Kendall Capital Management raised its stake in Merck & Co., Inc. (NYSE:MRK) by 15.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 11,943 shares of the company’s stock after buying an additional 1,640 shares during the quarter. Kendall Capital Management’s holdings in Merck & Co., Inc. were worth $921,000 at the end of the most recent reporting period.
A number of other hedge funds also recently added to or reduced their stakes in MRK. Norges Bank purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $2,250,767,000. Nuveen Asset Management LLC grew its stake in Merck & Co., Inc. by 20.4% in the fourth quarter. Nuveen Asset Management LLC now owns 24,251,965 shares of the company’s stock valued at $1,983,811,000 after purchasing an additional 4,112,158 shares in the last quarter. Morgan Stanley increased its position in Merck & Co., Inc. by 16.7% in the 4th quarter. Morgan Stanley now owns 22,569,366 shares of the company’s stock worth $1,846,174,000 after purchasing an additional 3,221,509 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Merck & Co., Inc. by 0.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,956,192 shares of the company’s stock worth $1,550,617,000 after purchasing an additional 139,485 shares in the last quarter. Finally, California Public Employees Retirement System lifted its holdings in shares of Merck & Co., Inc. by 31.6% during the 4th quarter. California Public Employees Retirement System now owns 13,542,412 shares of the company’s stock valued at $1,107,769,000 after buying an additional 3,252,367 shares during the last quarter. Institutional investors own 72.86% of the company’s stock.
A number of equities analysts recently commented on MRK shares. Cantor Fitzgerald restated an “overweight” rating on shares of Merck & Co., Inc. in a report on Friday, February 5th. SVB Leerink dropped their price target on shares of Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating on the stock in a research note on Thursday, May 6th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Merck & Co., Inc. presently has an average rating of “Buy” and a consensus target price of $97.50.
Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 29th. The company reported $1.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.23). The firm had revenue of $12.08 billion during the quarter, compared to analyst estimates of $12.71 billion. Merck & Co., Inc. had a net margin of 24.33% and a return on equity of 53.83%. The business’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.50 earnings per share. As a group, equities analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.
In other news, EVP Frank Clyburn sold 19,324 shares of Merck & Co., Inc. stock in a transaction dated Monday, May 10th. The stock was sold at an average price of $78.32, for a total value of $1,513,455.68. Company insiders own 0.28% of the company’s stock.
Merck & Co., Inc. Company Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.
Further Reading: What Does a Sell-Side Analyst Rating Mean?
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.